Compare Nucor Corporation (NUE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nucor Corporation vs Twist Bioscience Corp — how do they compare? Nucor Corporation trades at $274.49 (market cap $61.93B), while Twist Bioscience Corp trades at $125.28 (market cap $7.72B). The key difference: Nucor Corporation is far larger — about 8× Twist Bioscience Corp's market cap, and Nucor Corporation pays a 0.82% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NUE | TWST | |
|---|---|---|
Market Cap | $61.93B | $7.72B |
Sector | Basic Materials | Health |
52-Week High | $274.74 | $124.88 |
52-Week Low | $131.78 | $24.16 |
Enterprise Value | $66.34B | $7.65B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nucor (NUE) trades at $274.61, up 0.73% today, with a bullish technical outlook and strong earnings beats in Q1 and Q2 2026. The stock shows robust fundamentals with a P/E of 21.7 and net income margin of 7.99%, supported by record steel shipments and higher prices. Recent news highlights its position near buy points and resilience in industrial demand.
Outlook is positive with analyst consensus favoring buy ratings (59.37%) and a $279.63 price target. Risks include cyclical steel demand and tariff impacts, but earnings growth and institutional support provide upside potential for investors seeking exposure to industrial recovery.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nucor Corporation
Nucor Corp manufactures steel and steel products. The company also produces direct reduced iron for use in its steel mills. The operations include international trading and sales companies that buy and sell steel and steel products manufactured by the company and others. The operating business segments are: steel mills, steel products and raw materials, the steel mills segment derives maximum revenue.
Read more on NUE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
